Glutamate and Depression: Clinical and Preclinical Studies

Annals of the New York Academy of Sciences

Volumn 1003, Issue , 2003, Pages 250-272

  Paul, Ian A ^a,c   Skolnick, Phil ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b DOV Pharmaceuticals   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

AMPA receptor; Antidepressant treatment; Excitatory amino acid transmitter; Metabotropic glutamate receptor; Neuroplastic responses; Nitric oxide synthase; NMDA receptor

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 7 NITROINDAZOLE; AMINO ACID; AMINO ACID RECEPTOR; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; ASPARTIC ACID; BIOLOGICAL MARKER; CALCIUM; CYCLOSERINE; DEXAMETHASONE; FLUOXETINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; LY 392098; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; MONOAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; NITRIC OXIDE SYNTHASE; PAROXETINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CALCIUM HOMEOSTASIS; CONFERENCE PAPER; DATA ANALYSIS; DEPRESSION; DISEASE MODEL; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SELECTIVITY; EXCITATION; HUMAN; LOCUS CERULEUS; MAJOR DEPRESSION; METABOLISM; NEUROTRANSMISSION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; STRESS; SUICIDAL BEHAVIOR; SYMPTOM; SYNAPSE;

EID: 0346461630     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1300.016     Document Type: Conference Paper

References (190)

1. 1994. Diagnostic and statistical manual of mental disorders, Fourth edition (DSM-IV). American Psychiatric Association. Washington, D.C.
2. MUSSELMAN, D.L., D.L. EVANS & C.B. NEMEROFF. 1998. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry 55: 580-592.
3. SCHULZ, R. et al. 2000. Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch. Intern. Med. 160: 1761-1768.
4. MICHELSON, D., et al. 1996. Bone mineral density in women with depression. N. Engl. J. Med. 335: 1176-1181.
5. CIECHANOWSKI, P.S., W.J. KATON & J.E. Russo. 2000. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med. 160: 3278-3285.
6. REGIER, D.A. et al. 1993. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psychiatry. 50: 85-94.
7. STONE, E.A. 1983. Problems with the current catecholamine hypothesis of antidepressant agents: speculations leading to a new hypothesis. Behav. Brain Sci. 6: 555-577.
8. MAJ, J., E. PRZEGALINSKI & E. MOGILNICKA. 1984. Hypotheses concerning the mechanism of action of antidepressant drugs. Rev. Physiol. Biochem. Pharmacol. 100: 1-74.
9. CALDECOTT-HAZARD, S. et al. 1991. Clinical and biochemical aspects of depressive disorders - II. Transmitter/receptor theories. Synapse 9: 251-301.
10. CHARNEY, D.S. 1998. Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry. 14: 11-14.
11. OSWALD, I., V. BREZINOVA & D.L.F. DUNLEAVY. 1972. On the slowness of action of tricyclic antidepressant drugs. Br. J. Psychiat. 120: 673-677.
12. DUMAN, R.S., G.R. HENINGER & E.J. NESTLER. 1997. A molecular and cellular theory of depression. Arch. Gen. Psychiatry. 54: 597-606.
13. ROSSBY, S.P. & F. SULSER. 1997. Antidepressants: Beyond the synapse. In Antidepressants: New Pharmacological Strategies. P. Skolnick, Ed.: 195-212. Humana Press. Totowa, NJ.
14. MANJI, H.K., W.C. DREVETS & D.S. CHARNEY. 2001. The cellular neurobiology of depression. Nat. Med. 7: 541-547.
15. SKOLNICK, P. 1999. Antidepressants for the new millennium. Eur. J. Pharmacol. 375: 31-40.
16. WATKINS, J.C. 2000. L-glutamate as a central neurotransmitter: looking back. Biochem. Soc. Trans. 28: 297-309.
17. RAJKOWSKA, G. 2000. Histopathology of the prefrontal cortex in major depression: what does it tell us about dysfunctional monoaminergic circuits? Prog. Brain Res. 126: 397-412.
18. KIM, J.S. et al. 1982. Increased serum glutamate in depressed patients. Arch. Psychiatr. Nervenkr. 232: 299-304.
19. ALTAMURA, C.A. et al. 1993. Plasma and platelet excitatory amino acids in psychiatric disorders. Neuroscience 55: 511-519.
20. MAURI, M.C. et al. 1998. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 37: 124-129.
21. MAES, M. et al. 1998. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr. Scand. 97: 302-308.
22. BERK, M., H. PLEIN & D. FERREIRA. 2001. Platelet glutamate receptor supersensitivity in major depressive disorder. Clin. Neuropharmacol. 24: 129-132.
23. AUER, D.P. et al. 2000. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry. 47: 305-313.
24. 2+-dependent release in intractable depression assessed antemortem. Brain Res. 494: 315-324.
25. MURCK, H. et al. 2002. Increase in amino acids in the pons after sleep deprivation: a pilot study using proton magnetic resonance spectroscopy. Neuropsychobiology 45: 120-123.
26. MICHAEL, N. et al. 2003. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. Neuropsychopharmacology 28: 720-725.
27. PFLEIDERER, B. et al. 2003. Effective electroconvulsive therapy reverses glutamate/ glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res. 122: 185-192.
28. ORTOLANO, G.A. et al. 1983. A calcium hypothesis of antidepressant action. Med. Hypoth. 10: 207-221.
29. CLARK, J.A., L.J. DAVIDSON & H.C. FERGUSON. 1962. Psychosis in hypoparathyroidism. J. Mental Sci. 108: 811-815.
30. FOURMAN, P. et al. 1967. Effect of calcium on mental symptoms in partial parathyroid insufficiency. Lancet 2: 914-915.
31. WHYBROW, P.C. & T. HURWITZ. 1976. Psychological disturbances associated with endocrine disease and hormone therapy. In Hormones, Behavior, and Psychopathology. E.J. Sachar, Ed.: 125-143. Raven Press. New York.
32. GOUR, K.N. & H.M. CHAUDRY. 1957. Study of calcium metabolism in electric convulsive therapy (ECT) in certain. J. Mental Sci. 103: 275-285.
33. FLACH, F.F., E. LIANG & P.E. STOKES. 1960. The effects of electric convulsive treatments on nitrogen, calcium, and phosphorus. J. Mental Sci. 106: 638-647.
34. FLACH, F.F. 1964. Calcium metabolism in states of depression. Br. J. Psychiatr. 110: 588-593.
35. FARAGALLA, F.F. & F.F. FLACH. 1970. Studies of mineral metabolism in mental depression. I. The effects of imipramine and electric convulsive therapy on calcium balance and kinetics. J. Nerv. Ment. Dis. 151: 120-129.
36. JIMERSON, D.C. et al. 1979. CSF Calcium: Clinical correlates in affective illness and schizophrenia. Biol. Psychiatry 14: 37-51.
37. CARMAN, J.S. et al. 1977. Calcium and electroconvulsive therapy in severe depressive illness. Biol. Psychiatry 12: 5-17.
38. CARMAN, J.S. & R.J. WYATT. 1979. Calcium: Bivalent cation in the bivalent psychoses. Biol. Psychiatry 14: 295-336.
39. LINDER, J. et al. 1989. Calcium and magnesium concentrations in affective disorder: difference between plasma and serum in relation to symptoms. Acta Psychiatr. Scand. 80: 527-537.
40. DUBOVSKY, S.L. et al. 1989. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch. Gen. Psychiatry 46: 632-638.
41. EIDUSON, S., N.Q. BRILL & E. CRUMPTON. 1960. The effect of electro-convulsive therapy on spinal fluid constituents. J. Mental Sci. 106: 692-698.
42. CARMAN, J.S. & R.J. WYATT. 1977. Alterations in cerebrospinal fluid and serum total calcium with changes in psychiatric state. In Neuroregulators and Psychiatric Disorders. E. Usdin et al., Eds. Oxford University Press. New York.
43. MELLERUP, E.T. et al. 1979. Calcium and electroconvulsive therapy of depressed patients. Biol. Psychiatry 14: 711-714.
44. DUBOVSKY, S.L., R.D. FRANKS & D. SCHRIER. 1985. Phenelzine-induced hypomania: Effect of verapamil. Biol. Psychiatry 20: 1009-1014.
45. DUBOVSKY, S.L. 1993. Calcium antagonists in manic-depressive illness. Neuropsychobiology 27: 184-192.
46. SILLS, M.A. & P.S. LOO. 1988. Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate. Mol. Pharmacol. 36: 160-165.
47. REYNOLDS, I.J. & R.J. MILLER. 1988. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br. J. Pharmacol. 95: 95-102.
48. KIM, J.S. et al. 1982. Effects of amitriptyline on serum glutamate and free tryptophan in rats. Arch. Psychiatr. Nervenkr. 232: 391-394.
49. PRIKHOZHAN, A.V., G.I. KOVALEV & K.S. RAEVSKII. 1990. [Effects of antidepressive agents on glutamatergic autoregulatory presynaptic mechanism in the rat cerebral cortex], Biull. Eksp. Biol. Med. 110: 624-626.
50. McCASLIN, P.P. et al. 1992. Amitriptyline prevents N-methyl-D-aspartate (NMDA)-induced toxicity, does not prevent NMDA-induced elevations of extracellular glutamate, but augments kainate-induced elevations of glutamate. J. Neurochem. 59: 401-405.
51. BOURON, A. & J.Y. CHATTON. 1999. Acute application of the tricyclic antidepressant desipramine presynaptically stimulates the exocytosis of glutamate in the hippocampus. Neuroscience 90: 729-736.
52. GOLEMBIOWSKA, K. & A. ZYLEWSKA. 1999. Effect of antidepressant drugs on veratridine-evoked glutamate and aspartate release in rat prefrontal cortex. Pol. J. Pharmacol. 51: 63-70.
53. BORTOLOTTO, Z.A., S.M. FITZJOHN & G.L. COLLINGRIDGE. 1999. Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Curr. Opin. Neurobiol. 9: 299-304.
54. COLLINGRIDGE, G.L. & T.V. BLISS. 1995. Memories of NMDA receptors and LTP. Trends Neurosci. 18: 54-56.
55. SHORS, T.J. et al. 1989. Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus. Science 244: 224-226.
56. TRULLAS, R. & P. SKOLNICK. 1990. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185: 1-10.
57. PETRIE, R.X., I.C. REID & C.A. STEWART. 2000. The N-methyl-D-aspartate receptor, synaptic plasticity, and depressive disorder. A critical review. Pharmacol. Ther. 87: 11-25.
58. TRULLAS, R., B. JACKSON & P. SKOLNICK. 1989. 1- aminocyclopropanecarboxylic acid, a ligand of the strychnine-insensitive glycine receptor. Pharmacol. Biochem. Behav. 34: 313-316.
59. TRULLAS, R. et al. 1991. 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 203: 379-385.
60. LAYER, R.T. et al. 1995. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 52: 621-627.
61. TRULLAS, R. 1997. Functional NMDA antagonists: A new class of antidepressant agents. In Antidepressants: New Pharmacological Strategies. P. Skolnick, Ed.: 103-124. Humana Press. Totowa, NJ.
62. MAJ, J., Z. ROGOZ & G. SKUZA. 1992. The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats. Pol. J. Pharmacol. Pharm. 44: 217-226.
63. MAJ, J. et al. 1992. The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test. Pol. J. Pharmacol. Pharm. 44: 337-346.
64. 2+ levels in neuronal culture. Eur. J. Pharmacol. 219: 53-57.
65. MAJ, J. et al. 1992. Effects of MK-801 and antidepressant drugs in the forced swimming test in rats. Eur. Neuropsychopharmacol. 2: 37-41.
66. WEDZONY, K., V. KLIMEK & G. NOWAK. 1995. Rapid down-regulation of beta-adrenergic receptors evoked by combined forced swimming test and CGP 37849 - a competitive antagonist of NMDA receptors. Pol. J. Pharmacol. 47: 537-540.
67. PRZEGALINSKI, E. et al. 1997. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 36: 31-37.
68. KROCZKA, B. et al. 2001. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res. Bull. 55: 297-300.
69. PAPP, M. & E. MORYL. 1994. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol. 263: 1-7.
70. MJELLEM, N., A. LUND & K. HOLE. 1993. Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice. Neuropharmacology 32: 591-595.
71. MELONI, D. et al. 1993. Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol. Biochem. Behav. 46: 423-426.
72. MAJ, J. et al. 1995. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. Pol. J. Pharmacol. 47: 501-507.
73. OSSOWSKA, G., B. KLENK-MAJEWSKA & G. SZYMCZYK. 1997. The effect of NMDA antagonists on footshock-induced fighting behavior in chronically stressed rats. J. Physiol. Pharmacol. 48: 127-135.
74. KELLY, J.P., A.S. WRYNN & B.E. LEONARD. 1997. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74: 299-316.
75. YILMAZ, A. et al. 2002. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav. 71: 341-344.
76. PAUL, I.A. et al. 1992. Down-regulation of cortical beta-adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology 106: 285-287.
77. MAJ, J. et al. 1993. Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity. Pol. J. Pharmacol. 45: 455-466.
78. PAPP, M., V. KLIMEK & P. WILLNER. 1994. Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology (Berl). 114: 309-314.
79. MAJ, J., Z. ROGOZ & G. SKUZA. 1991. Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats. J. Neural Transm. Gen. Sect. 85: 169-179.
80. MAJ, J. et al. 1992. The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. Neuropharmacology 31: 685-691.
81. PAUL, I.A. et al. 1993. Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine. Eur. J. Pharmacol. 247: 305-311.
82. MASSICOTTE, G., J. BERNARD & M. OHAYON. 1993. Chronic effects of trimipramine, an antidepressant, on hippocampal synaptic plasticity. Behav. Neural Biol. 59: 100-106.
83. NOWAK, G. et al. 1993. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J. Pharmacol. Exp. Ther. 265: 1380-1386.
84. PAUL, I.A. et al. 1994. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269: 95-102.
85. BERNARD, J., M. OHAYON & G. MASSICOTTE. 1994. Modulation of the AMPA receptor by phospholipase A2: effect of the antidepressant trimipramine. Psychiatry Res. 51: 107-114.
86. PILC, A. & B. LEGUTKO. 1995. Antidepressant treatment influences cyclic AMP accumulation induced by excitatory amino acids in rat brain. Pol. J. Pharmacol. 47: 359-361.
87. PILC, A. & B. LEGUTKO. 1995. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. Neuroreport 7: 85-88.
88. SKOLNICK, P. et al. 1996. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29: 23-26.
89. WATKINS, C.J., Q. PEI & N.R. NEWBERRY. 1998. Differential effects of electroconvulsive shock on the glutamate receptor mRNAs for NR2A, NR2B and mGluR5b. Brain Res. Mol. Brain Res. 61: 108-113.
90. NOWAK, G. et al. 1998. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur. J. Pharmacol. 342: 367-370.
91. BOYER, P.A., P. SKOLNICK & L.H. FOSSOM. 1998. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J. Mol. Neurosci. 10: 219-233.
92. BRANDOLI, C. et al. 1998. Brain-derived neurotrophic factor and basic fibroblast growth factor downregulate NMDA receptor function in cerebellar granule cells. J. Neurosci. 18: 7953-7961.
93. NOWAK, G. et al. 1995. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J. Neurochem. 64: 925-927.
94. PAUL, I.A. 1997. NMDA receptors and affective disorders. In Antidepressants: New Pharmacological Strategies. P. Skolnick, Ed.: 145-158. Humana Press. Totowa, NJ.
95. NOWAK, G., G.A. ORDWAY & I.A. PAUL. 1995. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 675: 157-164.
96. LAW, A.J. & J.F. DEAKIN. 2001. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12: 2971-2974.
97. CRANE, O.E. 1961. The psychotropic effects of cycloserine: A new use for an antibiotic. Compr. Psychiatry. 2: 51-59.
98. CRANE, G.E. 1959. Cycloserine as an antidepressant agent. Am. J. Psychiat. 115: 1025-1026.
99. VALE, S., M.A. ESPEJEL & J.C. DOMINGUEZ. 1971. Amantadine in depression. Lancet 2: 437.
100. BODE, L. et al. 1997. Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 349: 178-179.
101. RIZZO, M. & P.L. MORSELLI. 1972. Amantadine-induced aggressiveness. Br. Med. J. 3: 50.
102. PARKES, J.D. et al. 1970. Amantadine dosage in treatment of Parkinson's disease. Lancet 1: 1130-1133.
103. HUBER, T.J., D.E. DIETRICH & H.M. EMRICH. 1999. Possible use of amantadine in depression. Pharmacopsychiatry 32: 47-55.
104. STRYJER, R. et al. 2003. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int. Clin. Psychopharmacol. 18: 93-96.
105. BOUGEROL, T. et al. 1990. [Plasma levels of metapramine and its 3 major metabolites in patients with depression. Results and preliminary interpretations]. Encephale 16: 35-40.
106. AZORIN, J.M. et al. 1988. Plasma 3,4-dihydroxyphenylethyleneglycol and 3-methoxy-4-hydroxyphenylethyleneglycol as indicators of central noradrenergic activity. A comparative study on control subjects and depressed patients. Neuropsychobiology 20: 67-73.
107. GAYRAL, L.F. et al. 1978. [Therapeutic trial of the antidepressive agent, 19560 RP metapramine]. Therapie 33: 541-542.
108. DICK, P. 1978. [Comparative study of the pharmacological and clinical effects of clorimipramine and metaprimine (19560 R.P.)]. Encephale 4: 41-51.
109. BOIREAU, A. et al. 1996. The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors. Neuropharmacology 35: 1703-1707.
110. MORYL, E., W. DANYSZ & G. QUACK. 1993. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 72: 394-397.
111. GORTELMEYER, R. & H. ERBLER. 1992. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung 42: 904-913.
112. AMBROZI, L. & W. DANIELCZYK. 1988. Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a phase II double-blind study. Pharmacopsychiatry 21: 144-146.
113. BERMAN, R.M. et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47: 351-354.
114. KUDOH, A. et al. 2002. Small-dose ketamine improves the postoperative state of depressed patients. Anesth. Analg. 95: 114-118.
115. PILC, A. et al. 1998. Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. Eur. J. Pharmacol. 349: 83-78.
116. PALUCHA, A. et al. 1997. Influence of imipramine treatment on the group I of metabotropic glutamate receptors in CA1 region of hippocampus. Pol. J. Pharmacol. 49: 495-497.
117. ZAHORODNA, A. & M. BIJAK. 1999. An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur. J. Pharmacol. 386: 173-179.
118. TATARCZYNSKA, E. et al. 2001. Potential anxiolytic-and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132: 1423-1430.
119. BAJKOWSKA, M. et al. 1999. Effect of chronic antidepressant or electroconvulsive shock treatment on mGLuRla immunoreactivity expression in the rat hippocampus. Pol. J. Pharmacol. 51: 539-541.
120. SMIALOWSKA, M. et al. 2002. Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology 42: 1016-1023.
121. MATRISCIANO, F. et al. 2002. Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology 42: 1008-10015.
122. ZAFRA, F. et al. 1990. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J. 9: 3545-3550.
123. HAYASHI, T. et al. 1999. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397: 72-76.
124. LAUTERBORN, J.C. et al. 2000. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J. Neurosci. 20: 8-21.
125. ALTAR, C.A. 1999. Neurotrophins and depression. Trends Pharmacol. Sci. 20: 59-61.
126. LI, X. et al. 2001. Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40: 1028-1033.
127. LEGUTKO, B., X. LI & P. SKOLNICK. 2001. Regulation of BDNF expression in primary neuron culture by LY392098, a novel AMPA receptor potentiator. Neuropharmacology 40: 1019-10127.
128. MARTINEZ-TURRILLAS, R., D. FRECHILLA & J. DEL RIO. 2002. Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 43: 1230-1237.
129. SVENNINGSSON, P. et al. 2002. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 99: 3182-3187.
130. SOUTHAM, E. & J. GARTHWAITE. 1993. The nitric oxide-cyclic GMP signalling pathway in rat brain. Neuropharmacology 32: 1267-1277.
131. ZHU, X.Z. & L.G. LUO. 1992. Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices. J. Neurochem. 59: 932-935.
132. STRASSER, A. et al. 1994. L-arginine induces dopamine release from the striatum in vivo. Neuroreport 5: 2298-300.
133. BOWYER, J.F. et al. 1995. Nitric oxide regulation of methamphetamine- induced dopamine release in caudate/putamen. Brain Res. 699: 62-70.
134. LIN, A.M., L.S. KAO & C.Y. CHAI. 1995. Involvement of nitric oxide in dopaminergic transmission in rat striatum: an in vivo electrochemical study. J. Neurochem. 65: 2043-2049.
135. FILIP, M. & E. PRZEGALINSKI. 1998. The role of the nitric oxide (NO) pathway in the discriminative stimuli of amphetamine and cocaine. Pharmacol. Biochem. Behav. 59: 703-708.
136. GUEVARA-GUZMAN, R., P.C. EMSON & K.M. KENDRICK. 1994. Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J. Neurochem. 62: 807-810.
137. SILVA, M.T. et al. 1995. Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. Br. J. Pharmacol. 114: 257-258.
138. MONTAGUE, P.R. et al. 1994. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 263: 973-977.
139. HARVEY, B.E. 1996. Affective disorders and nitric oxide: A role in pathways to relapse and refractoriness? Human Psychopharmacol. 11: 309-319.
140. VAN AMSTERDAM, J.G. & A. OPPERHUIZEN. 1999. Nitric oxide and biopterin in depression and stress. Psychiatry Res. 85: 33-38.
141. LEE, S.-Y, O.-K. KIM & E.E. EL-FAKAHANY. 1995. Inhibition of neuronal nitric oxide synthase by antidepressants. Pharmacol. Comm. 7: 1-9.
142. WEGENER, G. et al. 2003. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 959: 128-134.
143. FINKEL, M.S. et al. 1996. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol. Bull. 32: 653-658.
144. MONCADA, S. & A. HIGGS. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329: 2002-2012.
145. JEFFERYS, D. & J. FUNDER. 1996. Nitric oxide modulates retention of immobility in the forced swimming test in rats. Eur. J. Pharmacol. 295: 131-135.
146. HARKIN, A.J. et al. 1999. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur. J. Pharmacol. 372: 207-213.
147. KAROLEWICZ, B. et al. 1999. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 2. Chronic treatment results in downregulation of cortical beta-adrenoceptors. Eur. J. Pharmacol. 372: 215-220.
148. YILDIZ, F. et al. 2000. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology (Berl). 149: 41-44.
149. EROGLU, L. & B. CAGLAYAN. 1997. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol. Res. 36: 381-385.
150. HEIBERG, I.L., G. WEGENER & R. ROSENBERG. 2002. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav. Brain Res. 134: 479-484.
151. SUZUKI, E. et al. 2002. Antipsychotic, antidepressant, anxiolytic, and anticonvulsant drugs induce type II nitric oxide synthase mRNA in rat brain. Neurosci. Lett. 333: 217-219.
152. SANCHEZ, F. et al. 1999. Swim stress enhances the NADPH-diaphorase histochemical staining in the para ventricular nucleus of the hypothalamus. Brain Res. 828: 159-62.
153. LUO, L. & R.X. TAN. 2001. Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model. Acta Pharmacol. Sin. 22: 865-870.
154. PLOTSKY, P.M., M.J. OWENS & C.B. NEMEROFF. 1998. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr. Clin. North Am. 21: 293-307.
155. SAPOLSKY, R.M. 2000. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol. Psychiatry 48: 755-765.
156. RAJKOWSKA, G. 2000. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 48: 766-777.
157. RAJKOWSKA, G. et al. 1999. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 45: 1085-1098.
158. ONGUR, D., W.C. DREVETS & J.L. PRICE. 1998. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. U S A 95: 13290-13295.
159. NIBUYA, M., S. MORINOBU & R.S. DUMAN. 1995. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15: 7539-7547.
160. NIBUYA, M., E.J. NESTLER & R.S. DUMAN. 1996. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 16: 2365-2372.
161. MANJI, H.K. et al. 2003. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53: 707-742.
162. MALBERG, J.E. et al. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20: 9104-9110.
163. ASTON-JONES, G. et al. 1986. The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 234: 734-737.
164. OLPE, H.R. et al. 1989. Excitatory amino acid receptors in rat locus coeruleus. An extracellular in vitro study. Naunyn Schmiedebergs Arch. Pharmacol. 339: 312-314.
165. SINGEWALD, N., G.Y. ZHOU & C. SCHNEIDER. 1995. Release of excitatory and inhibitory amino acids from the locus coeruleus of conscious rats by cardiovascular stimuli and various forms of acute stress. Brain Res. 704: 42-50.
166. TIMMERMAN, W. et al. 1999. Effects of handling on extracellular levels of glutamate and other amino acids in various areas of the brain measured by microdialysis. Brain Res. 833: 150-160.
167. SINGEWALD, N. et al. 1996. Corticotropin-releasing factor modulates basal and stress-induced excitatory amino acid release in the locus coeruleus of conscious rats. Neurosci. Lett. 204: 45-48.
168. LEVINE, J. et al. 2000. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry. 47: 586-593.
169. KALEN, P. et al. 1986. Further evidence for excitatory amino acid transmission in the lateral habenular projection to the rostral raphe nuclei: lesion-induced decrease of high affinity glutamate uptake. Neurosci. Lett. 68: 35-40.
170. TAO, R. & S.B. AUERBACH. 2000. Regulation of serotonin release by GABA and excitatory amino acids. J. Psychopharmacol. 14: 100-113.
171. KALIVAS, P.W., L. CHURCHILL & M.A. KLITENICK. 1993. The circuitry mediating the translation of motivational stimuli into adaptive motor responses. In Limbic Motor Circuits and Psychiatry. P.W. Kalivas & C.D. Barnes, Eds.: 237-287. CRC Press. Boca Raton, FL.
172. SWERDLOW, N.R. & G.F. KOOB. 1987. Dopamine, schizophrenia, mania and depression: Toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav. Brain Sci. 10: 197-245.
173. WATANABE, Y. et al. 2003. Post-synaptic density-95 promotes calcium/calmodulin-dependent protein kinase II-mediated Ser847 phosphorylation of neuronal nitric oxide synthase. Biochem. J. 372: 465-471.
174. CHRISTOPHERSON, K.S. et al. 1999. PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J. Biol. Chem. 274: 27467-27473.
175. SATTLER, R. et al. 1999. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science 284: 1845-1848.
176. XING, J., D.D. GINTY & M.E. GREENBERG. 1996. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 273: 959-963.
177. PENDE, M. et al. 1997. Neurotransmitter-and growth factor-induced cAMP response element binding protein phosphorylation in glial cell progenitors: role of calcium ions, protein kinase C, and mitogen-activated protein kinase/ribosomal S6 kinase pathway. J. Neurosci. 17: 1291-1301.
178. DAS, S. et al. 1997. NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture. Synapse 25: 227-233.
179. DING, J.M. et al. 1997. Resetting the biological clock: mediation of nocturnal CREB phosphorylation via light, glutamate, and nitric oxide. J. Neurosci. 17: 667-675.
180. PERKINTON, M.S. et al. 2002. Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erkl/2), Akt/PKB and CREB in striatal neurones. J. Neurochem. 80: 239-254.
181. PERKINTON, M.S., T.S. SIHRA & R.J. WILLIAMS. 1999. Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons. J. Neurosci. 19: 5861-5874.
182. EHLERS, M.D. 1999. Synapse structure: glutamate receptors connected by the shanks. Curr Biol. 9: R848-50.
183. Tu, J.C. et al. 1999. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23: 583-592.
184. HARDINGHAM, G.E., F.J. ARNOLD & H. BADING. 2001. Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat. Neurosci. 4: 261-267.
185. HARDINGHAM, G.E., Y. FUKUNAGA & H. BADING. 2002. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5: 405-414.
186. HARDINGHAM, G.E. & H. BADING. 2002. Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim. Biophys. Acta 1600: 148-153.
187. JODO, E., C. CHIANG & G. ASTON-JONES. 1998. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 83: 63-79.
188. JODO, E. & G. ASTON-JONES. 1997. Activation of locus coeruleus by prefrontal cortex is mediated by excitatory amino acid inputs. Brain Res. 768: 327-332.
189. SINGEWALD, N. & A. PHILIPPU. 1998. Release of neurotransmitters in the locus coeruleus. Prog Neurobiol. 56: 237-67.
190. PEYRON, C. et al. 1998. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 82: 443-468.